President and Chief Executive Officer
Shervin brings to BVI over 20 years of general management, operational, financial, and investment experience across a diverse array of industries including healthcare, consumer products, industrial manufacturing and financial services. His experiences also span internationally including the US, Switzerland, France, Ireland and the United Kingdom. Prior to BVI, Shervin was a senior executive with Swiss headquartered Novartis Group AG, one of the largest global healthcare companies, holding roles which included Global Head of Corporate Finance and several country/regional commercial roles. Before Novartis, he started his career and spent 15 years with The Blackstone Group, one of the world’s leading alternative investment firms, most recently as a Managing Director with experience in both the Restructuring and Private Equity businesses. He currently serves on the Board of Directors of BVI (member of the Compensation Committee), Hain Celestial (Nasdaq: HAIN; chair of the Audit Committee and member of the Strategy Committee) and Motus GI (Nasdaq: MOTS; chair of the Audit Committee). In addition, Shervin serves on the Wharton Leadership Advisory Board, established by the Center for Leadership and Change Management at the University of Pennsylvania. Shervin is a graduate of the Wharton School of the University of Pennsylvania.
Chief Financial Officer
David is a highly regarded finance executive with over 30 years of experience spanning the Medical Device, Pharmaceutical, Automotive, Banking and Oil industries. During this time, he has had the opportunity to further his career in the diverse cultures of the UK, Switzerland, US, Japan and Spain. Before joining BVI, David was Chief Financial Officer(CFO) at Alcon (a division of Novartis) where he was instrumental in preparing the company for it’s $30bn highly successful spinoff. He also served as the CFO for Vaccines and Diagnostics and Pharma divisions within Novartis over 19 years. Prior to Novartis, he was with General Motors, Swiss Bank and BP. David is a graduate of Aberdeen University, where he graduated with an MA in Economics and Accounting and is also a Fellow of the Chartered Management Accountants.
Andrew (Andy) Dawson
Chief Human Resources Officer
Andrew (Andy) Dawson brings more than 20 years of experience in human resource strategy and management with some of the world’s leading Healthcare and Biopharma companies. Mr. Dawson started his career in Human Resources with Eli Lilly and Company and continued to grow his career through progressive HR leadership roles at both Novartis and Roche around the globe, including the formation of the Vaccines and Diagnostics Business following Novartis' acquisition of Chiron. Upon joining Shire in 2014, he played a key leadership role in re-imagining the global HR function during a significant time of transformation. While there, he helped lead the organization through significant change and growth following numerous mergers and acquisitions including the leadership of the new global site strategy following the $32bn acquisition of Baxalta, and the design and execution of the new organization design for the expanded company. Following this, Mr Dawson held roles of increasing scope and responsibility at TripAdvisor and most recently leading the Human Resources function for emerging, pre-commercial companies in the Biotech space. Mr Dawson is a member of the Forbes HR Leadership Council, serves on the advisory board(s) for LEAP HR and BioPharma Talent / CBI. Mr Dawson holds a Masters Degree in Human Resources Management and Development from the University of Salford (Manchester, UK).
Vice President, Global Operations
Christine Lucas brings more than 20 years of progressive experience in global operations including manufacturing, supply chain and engineering. Serving most recent as Vice President of Operations at Zimmer Biomet Holding, Inc., where she was focused was on end-to-end global supply chain, operations excellence and new product introductions. Christine was responsible for leading the Dental business unit supply chain organization including its global distribution and manufacturing footprint. Prior to Zimmer, Christine held a variety of operating roles at Biomet 3i, Boston Scientific and King Systems. Christine earned an Associate of Science degree in Manufacturing and Mechanical Engineering from the Institute Universitaire de Technologie in France and a Bachelor of Science degree in Biomedical Engineering from the Université deTechnologie in Compiègne, France.
Vice President, US Sales
Darin Dixon brings over 22 years of sales and sales leadership in both global and domestic capacities with the majority of his career in the Ophthalmology sector. Prior to BVI, Darin led AcuFocus as the Vice President of Global Sales through FDA approval and effectively commercialized the KAMRA™ Corneal Inlay as a disruptive, first of its kind technology within the corneal and refractive markets. Prior to AcuFocus, he served as Vice President of US Sales at MicroSurgical Technologies (MST) managing all direct, and distributor sales teams. Most of his career in ophthalmology, he served as a Senior Director at Abbott Medical Optics (AMO) with increasing responsibilities over its US cataract, refractive, and premium surgical business units. Prior to medical devices, he held several senior director level positions with a successful track record within the Executive Search industry. Darin earned a B.A. from University of Utah with a major in Organizational Communications and minor in Japanese.
Vice President, International
Denis Hinaut brings more than 30 years of experience in sales, marketing, dealer management, and sales management in the medical field. Prior to Beaver-Visitec, Mr. Hinaut served as Director of International Sales and Marketing for BD Medical-Ophthalmic Systems. In 2000, he was given the task to develop and build the BD ophthalmic business in Europe. He successfully grew the European region to be the largest worldwide for BD in sales and revenue. Mr. Hinaut has a Bachelor's degree in Business and Economics from ESC Lille, France.
Devang V. Shah, Ph.D.
Vice President, Global R&D, Regulatory Affairs and Quality Assurance
Devang Shah brings to BVI more than thirteen years of experience building and leading teams in medical device R&D, Strategy and Business Development. Throughout his tenure at Bard, Devang held roles of increasing responsibility focused on creating and executing against product development pipelines that addressed significant unmet clinical needs and delivered organic revenue growth. While co-leading Bard's Tissue Regeneration Franchise, Devang and his team supported the development and commercial launch of innovative new product lines which have generated organic revenues of >$100 million. His career began at Boston Scientific as a Consultant in the Urology & Women's Health Division. He earned a Bachelor of Science degree in Biomedical Engineering from Worcester Polytechnic Institute followed by a Master of Engineering in Chemical Engineering from Tufts University. He subsequently earned a Ph.D. in Molecular Biology from Northeastern University and an MBA from the MIT Sloan School of Management.
President, Vitreq Innovation Unit
Frank Ruseler has over 25 years of experience in global sales, marketing, business development and general management within the surgical ophthalmic medical device industry. He specializes in driving surgical ophthalmic innovations from ideas through to final commercial products for launch into the worldwide market. He has built strong relationships with many renowned key opinion leaders worldwide. Since 2015, Frank has been CEO and co-founder of Vitreq® a first-class ophthalmic medical device company producing state-of-the-art vitreoretinal surgical products. Vitreq became part of BVI in July 2017 and continues to partner with surgeons to innovate vitreoretinal products.
Sr Director, Business Development, Legal & Transformation
Jean-Nicolas (“JN”) Fassin has 15 years of experience in M&A, corporate finance, strategy and law. He joined the BVI leadership team following the acquisition of PhysIOL® by BVI in late 2018. Prior to joining PhysIOL® in 2017, JN was a Senior Manager at BDO Corporate Finance in Belgium advising clients on small- and mid-sized M&A transactions, valuation and financial due diligence across various industries. He also worked as management consultant at McKinsey & Company focusing on strategy assignments and as lawyer in top tier law firms advising clients on M&A, litigation and corporate law matters. He has an MBA from London Business School, an LLM from Columbia Law School and is a graduate of Sciences Po Paris and the University of Liège, Faculty of Law.
Lars T. Bonefeld
Vice President, Global Marketing
Lars has 20 years of international life sciences operating experience including at Novartis where he held roles of increasing responsibility most recently as the Business Unit Head of Pharmaceuticals for Alcon UK/Ireland and Vice President of US Marketing for Novartis Vaccines. Lars has significant product launch and commercialization experience at Global and country level and has worked across marketing, sales, market access, and supply chain. In addition, he has worked as a management consultant, including as Associate Principal at McKinsey & Company, advising senior Life Sciences executives and private equity clients on operational effectiveness and business strategy. Lars has a Master of Science degree in Engineering from the Technical University of Denmark, Copenhagen.
Marc Nolet de Brauwere
President, PhysIOL Innovation Unit
Marc Nolet de Brauwere has over 20 years of experience in product development, business growth and operational leadership in the ophthalmic device industry, specifically in the area of intraocular lenses (IOLs) for cataract surgery. He acquired PhysIOL® in 1997 and has led the organization through industry leading growth and with consistent innovative product development designs and launches including the world’s first trifocal IOL. Marc holds both a Bachelor’s and Master’s degree in Civil Engineering.